Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

801
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
801
Tissue Transplantation01:24

Tissue Transplantation

850
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
850

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Defining intensive care status in metastatic lung cancer patients: A French survey.

Respiratory medicine and research·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Bone marrow transplantation·2026
Same author

[Do chemotherapies still have a place in the era of precision medicine?]

Bulletin du cancer·2026

Related Experiment Video

Updated: Jan 6, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K

[Intestinal microbiota and allogeneic stem cell transplantation].

Aurore Dougé1, Jacques-Olivier Bay1, Aurélie Ravinet2

  • 1Centre hospitalier universitaire Estaing, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.

Bulletin Du Cancer
|October 5, 2019
PubMed
Summary

Allogeneic stem cell transplants can cure leukemia but risk complications like infection. Restoring gut microbiota with fecal transplants may mitigate these risks by improving intestinal health.

Keywords:
Allogeneic hematopoïetic stem cell transplantationAllogreffe de cellules souches hématopoïétiquesFecal microbiota transplantationGraft-versus host diseaseIntestinal microbiotaMicrobiote intestinalRéaction du greffon contre l’hôteTransplantation de microbiote fécal

More Related Videos

Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.3K
Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E
09:48

Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E

Published on: September 26, 2019

16.5K

Related Experiment Videos

Last Updated: Jan 6, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K
Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.3K
Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E
09:48

Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E

Published on: September 26, 2019

16.5K

Area of Science:

  • Hematology
  • Microbiology
  • Immunology

Background:

  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment for acute leukemia.
  • HSCT is associated with significant complications, including infections and graft-versus-host disease (GVHD).
  • Intestinal microbiota alterations in HSCT recipients are increasingly linked to these adverse outcomes.

Purpose of the Study:

  • To review the role of intestinal microbiota in HSCT complications.
  • To explore the potential of fecal microbiota transplantation (FMT) as a therapeutic strategy.
  • To summarize current literature on FMT in the context of allogeneic HSCT.

Main Methods:

  • Literature review of studies on intestinal microbiota, HSCT complications, and FMT.
  • Analysis of the impact of conditioning regimens on gut microbiota.
  • Evaluation of FMT efficacy for restoring microbiota and preventing complications.

Main Results:

  • Conditioning regimens during HSCT impair the protective functions of the gut microbiota.
  • Microbiota dysbiosis is associated with increased risk of infection and GVHD post-HSCT.
  • Fecal microbiota transplantation has demonstrated efficacy in treating Clostridium difficile infection and shows promise in HSCT.

Conclusions:

  • Restoring a healthy intestinal microbiota is crucial for mitigating HSCT complications.
  • Fecal microbiota transplantation represents a promising approach to address microbiota impairment in HSCT recipients.
  • Further research is warranted to optimize FMT protocols for HSCT patients.